Lung Cancer Screening: 20,000 Targeted Tests to Start in March 2026
France is moving toward a nationwide lung cancer screening program, with initial targeted screenings set to begin in March 2026. The initiative, announced by Health Minister Stéphanie Rist on February 4, 2026, aims to replicate the success of existing screening programs for breast and colon cancer.
Expanding Lung Cancer Screening
Currently, only 20% of patients diagnosed with lung cancer in France survive five years after diagnosis. The government’s goal is to implement generalized lung cancer screening by 2030. This will begin with a pilot program involving over 20,000 individuals who will be screened in a targeted manner.
The initial phase will help determine which French citizens should be prioritized for screening, paving the way for a broader, population-level approach. The screening process is expected to utilize lung scans, potentially specialized ones, with further details to be released in March.
Additional Screening Initiatives
Alongside the lung cancer screening program, a new experimental program will target individuals at high risk for breast cancer. This demonstrates a broader commitment to proactive cancer detection and prevention. President Emmanuel Macron is expected to announce the resources and priorities dedicated to the fight against cancer on February 4, 2026.
Minister Rist highlighted the country’s investment of over one billion euros in cancer research, screening, and treatment, emphasizing France’s commitment to “sovereign” healthcare solutions.
Frequently Asked Questions
When will the targeted lung cancer screenings begin?
Targeted lung cancer screenings will begin in March 2026, with over 20,000 people expected to participate.
What is the ultimate goal of this initiative?
The ultimate goal is to achieve generalized lung cancer screening across France by 2030.
What type of screening will be used?
The screening is expected to be based on lung scans, potentially specialized scans, with more details to be announced in March 2026.
As France prepares to roll out this ambitious screening program, what impact do you foresee on early cancer detection rates and patient outcomes?